Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2021-12-31 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of certain pharmaceutical products passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug specifications, regulatory approvals, market impact, and risk warnings. The document is relatively short (1304 characters) and does not contain financial statements or detailed financial data. It is an announcement about regulatory approval and its impact rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-31 Chinese
哈药集团股份有限公司九届十次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board resolution regarding the granting of reserved stock options and restricted shares under a stock incentive plan. It includes details about the meeting, voting results, compliance with laws and regulations, and specifics of the stock option and restricted stock grants. The document is short (1106 characters) and serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis, nor is it a report publication or certification. The content fits best under Board/Management Information (MANG) as it relates to management decisions and board resolutions about stock incentives.
2021-12-30 Chinese
宁波小多信息咨询有限公司关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划预留授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2021 stock option and restricted stock incentive plan reserved grant matters of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It contains detailed explanations of the stock option and restricted stock incentive plan, including definitions, approval procedures, grant conditions, specific grant details, performance targets, and the impact on financial results. The document is comprehensive, over 12,000 characters, and includes detailed financial and operational conditions related to the incentive plan. It is not a simple announcement or a brief summary but a full advisory report analyzing the stock incentive plan. This type of document fits the category of an Audit Report / Information (AR) because it is a standalone financial advisory report related to accounting and financial incentives, not a full annual or quarterly report, nor a regulatory filing or announcement. Therefore, the best classification is AR with high confidence. FY 2021
2021-12-30 Chinese
哈药集团股份有限公司2021年股票期权与限制性股票激励计划预留授予激励对象名单（授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement of the allocation of stock options and restricted stock incentives to key technical personnel of 哈药集团股份有限公司 for the year 2021. It includes specific numbers of stock options and restricted shares granted, proportions relative to total stock, and lists of recipients. This type of document relates to share-based compensation plans and internal incentive allocations rather than financial results, management changes, or regulatory filings. It is not a full annual or interim report, nor an earnings release or proxy statement. It is a specific announcement about stock incentive plans, which fits best under the category of Share Issue/Capital Change (SHA), as it involves changes in share capital allocation through stock options and restricted stock grants.
2021-12-30 Chinese
哈药集团股份有限公司关于向激励对象授予预留部分股票期权与限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the grant of reserved stock options and restricted stocks to incentive recipients by 哈药集团股份有限公司. It includes specifics about the grant date, quantities, prices, conditions, approvals, legal opinions, and financial impacts related to the stock incentive plan. The content focuses on the company's equity incentive plan and its implementation details rather than financial results, earnings, or management discussions. It is not a full annual or interim report, nor is it a simple announcement of a report publication. It is also not a transcript, audit report, or legal proceeding update. The document is an official announcement about a capital-related event involving stock options and restricted stock grants, which fits the category of Capital/Financing Update (CAP).
2021-12-30 Chinese
哈药集团股份有限公司九届十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement regarding the approval of a stock option and restricted stock grant plan. It details the board meeting date, voting results, and specifics of the stock incentive plan. It references compliance with company law and internal regulations. The document is an official announcement of a board decision rather than a full report or financial statement. It does not contain financial results, audit information, or regulatory certifications. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management changes or actions.
2021-12-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.